Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - December 12, 2025 414 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the DESTINY-Breast05 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR What Is Pancreatic Enzyme Replacement Therapy in Cancer Care? June 22, 2021 What to Know About Exercising During Prostate Cancer: An Expert Q&A August 8, 2023 Easy Meals at Home October 23, 2020 Copanlisib Could Be a Viable Therapeutic Option for Select PIK3CA-Mutated Cancers May 25, 2022 Load more HOT NEWS Piecing together the puzzle: Antibiotics, the microbiome and bowel cancer Molecular Profiling Identifies Targetable Alterations in Majority of Patients with Advanced... 5-Yr-Old Has Cutest Celebration With Big Brother After Being Declared Cancer-Free. 確診癌症後患者應如何面對悲傷
